News

News

Jong Wang Kim, CEO of VAIM GLOBAL, "We will lead the global medical device market with JUVELOOK" [Interview]

Author
jo**********
Date
2024-04-24 13:42
Views
197


Jong Wang Kim, CEO of VAIM GLOBAL, "We will lead the global medical device market with JUVELOOK" [Interview]

A new trend has emerged in the ever-evolving landscape of beauty: slow aging. Unlike the concept of "anti-aging," which aims to prevent aging, slow aging encourages embracing the natural aging process while striving to maintain youthful and healthy skin for as long as possible. This shift in perspective has become a core focus in the beauty industry.

What is the reason for choosing PDLLA as an ingredient in Juvelook?

PDLLA is distinguished by its ability to add volume to the skin, typically by injecting it into the deeper layers to enhance volume. Before Juvelook, its primary applications were reducing wrinkles and providing lifting effects, essentially filling scars. In simpler terms, it has a scar-filling effect. We have decided to utilize this PDLLA ingredient by administering it thinly throughout the skin, providing comprehensive volumizing benefits.

What is the definition of Juvelook as a "skin booster"?

The key to cosmetic treatments is to change the appearance as well as the health of the skin. The first attempt at a skin booster started with the concern of how to inject fillers into the skin lightly. Skin boosters are a type of filler, but they can be seen as a more "light product." Juvelook is a skin booster that has received a grade 4 medical device based on the biodegradable polymer PDLLA. It decomposes naturally over time, so it can also secure stability.

What's your future goal?

We aim to broaden our business scope by introducing new categories. Initially, we are set to launch cosmetics tailored for hospitals in the first half of this year. Furthermore, we intend to diversify into medical aesthetics that offer enhanced comfort and usability. Our commitment extends to continually unveiling new products compatible with our existing medical devices.